ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Micreos raises funds for phage-derived skin-care antibiotics

by Ryan Cross
April 5, 2019 | APPEARED IN VOLUME 97, ISSUE 14

The Dutch company Micreos has raised about $34 million to further develop enzyme-based antibiotics called endolysins. The enzymes are normally made by bacteriophages, viruses that selectively kill specific strains of bacteria. The company already offers a nonprescription skin-care product called Gladskin containing endolysins that specifically kill the bacteria Staphylococcus aureus to treat conditions such as acne and eczema. Micreos plans to begin selling Gladskin in the US this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment